Polymorphism in the hMSH2 gene (gISV12-6T > C) is a prognostic factor in non-small cell lung cancer

Lung Cancer

Volumn 58, Issue 1, 2007, Pages 123-130

  Hsu, Han Shui ^a,b   Lee, I Hsuan ^c   Hsu, Wen Hu ^b   Kao, Wei Ting ^c   Wang, Yi Ching ^c,d  

^a NATIONAL YANG MING UNIVERSITY   (Taiwan)

^b TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^c NATIONAL TAIWAN NORMAL UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

hMSH2 gene; Immunohistochemistry; NSCLC; Polymorphism; Prognosis

Indexed keywords

PROTEIN MSH2;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER PATIENT; CANCER SURVIVAL; CIGARETTE SMOKING; CONTROLLED STUDY; DNA POLYMORPHISM; FEMALE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; SEX DIFFERENCE; TAIWAN;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROMOTER REGIONS (GENETICS); TAIWAN;

EID: 34548502273     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2007.04.018     Document Type: Article

References (36)

1. Department of Health, The executive Yuan, Republic of China. General Health Statistics, 2004. Health and Vital Statistics, Republic of China, R.O.C. Press, Taipei. 2005;92-115.
2. Mountain C.F. The international system for staging lung cancer. Semin Surg Oncol 18 (2000) 106-115
3. Shields P.G., and Harris C.C. Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J Clin Oncol 18 (2000) 2309-2315
4. Mohrenweiser H.W., and Jones I.M. Variation in DNA repair is a factor in cancer susceptibility: a paradigm for the promise and perils of individuals and population risk estimation?. Mutat Res 400 (1998) 15-24
5. Wei Q., Frazier M.L., and Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 92 (2000) 440-441
6. Zeng-Rong N., Paterson J., Alpert L., Tsao M.S., Viallet J., and Alaoui-Jamali M.A. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 55 (1995) 4760-4764
7. Fishel R., Lescoe M.K., Rao M.R.S., Copeland N.G., Jenkins N.A., Garber J., et al. The human mutator gene homolog MSH2 and its association with hereditary nonpolyposis colon cancer. Cell 75 (1993) 1027-1038
8. Leach F.S., Nicolaides N.C., Papadopoulos N., Liu B., Jen J., Parsons R., et al. Mutations of a mutS homolog in hereditary nonpolyposis colorectal cancer. Cell 75 (1993) 1215-1225
9. Papadopoulos N., Nicolaides N.C., Wei Y.F., Ruben S.M., Carter K.C., Rosen C.A., et al. Mutation of a mutL homolog in hereditary colon cancer. Science 263 (1994) 1625-1629
10. Xinarianos G., Liloglou T., Prime W., Maloney P., Callaghan J., Fielding P., et al. hMLH1 and hMSH2 expression correlates with allelic imbalance on chromosome 3p in non-small cell lung cancer. Cancer Res 60 (2000) 4216-4221
11. Xinarianos G., Liloglou T., Prime W., Sourvinos G., Karachristos A., Gosney J.R., et al. p53 status correlates with the differential expression of the DNA mismatch repair protein MSH2 in non-small cell lung carcinoma. Int J Cancer 101 (2002) 248-252
12. Hansen L.T., Thykjaer T., Ǿrntoft T.F., Rasmussen L.J., Keller P., Spang-Thomsen M., et al. The role of mismatch repair in small-cell lung cancer cells. Eur J Cancer 39 (2003) 1456-1467
13. Chang J.W., Chen Y.C., Chen C.Y., Chen J.T., Chen S.K., and Wang Y.C. Correlation of genetic instability with mismatch repair protein expression and p53 mutations in non-small cell lung cancer. Clin Cancer Res 6 (2000) 1639-1646
14. Hatta Y., Wada M., Takeuchi S., Tasaka T., Lee E., Lee Y.Y., et al. Mutational analysis of the hMSH2 gene in a wide variety of tumors. Int J Oncol 11 (1997) 465-469
15. Wang Y.C., Lu Y.P., Tseng R.C., Chang J.W., Chen J.T., Shih C.M., et al. Inactivation of hMLH1 and hMSH2 by promoter methylation in primary non-small cell lung tumors and matched sputum samples. J Clin Invest 111 (2003) 887-895
16. Hsu H.S., Wen C.K., Tang Y.A., Lin R.K., Li W.Y., Hsu W.H., et al. Promoter hypermethylation is the predominant mechanism in hMLH1 and hMSH2 deregulation and is a poor prognostic factor in nonsmoking lung cancer. Clin Cancer Res 11 (2005) 5410-5416
17. Worrillow L.J., Travis L.B., Smith A.G., Rollinson S., Smith A.J., Wild C.P., et al. An intron splice acceptor polymorphism in hMSH2 and risk of leukemia after treatment with chemotherapeutic alkylating agents. Clin Cancer Res 9 (2003) 3012-3020
18. Paz-y-Miño C., Pérez J.C., Fiallo B.F., and Leone P.E. A polymorphism in the hMSH2 gene (gIVS12-6T > C) associated with non-Hodgkin lymphomas. Cancer Genet Cytogenet 133 (2002) 29-33
19. Palicio M., Blanco I., Tórtola S., González I., Marcuello E., Brunet J., et al. Intron splice acceptor site polymorphism in the hMSH2 gene in sporadic and familial colorectal cancer. Brit J Cancer 82 (2000) 535-537
20. Goessl C., Plaschke J., Pistorius S., Hahn M., Frank S., Hampl M., et al. An intronic germline transition in the HNPCC gene hMSH2 is associated with sporadic colorectal cancer. Eur J Cancer 33 (1997) 1869-1874
21. Brentnall T.A., Rubin C.E., Crispin D.A., Stevens A., Batchelor R.H., Haggitt R.C., et al. A germline substitution in the human MSH2 gene is associated with high-grade dysplasia and cancer in ulcerative colitis. Gastroenterology 109 (1995) 151-155
22. Jung C.Y., Choi J.E., Park J.M., Chae M.H., Kang H.G., Kim K.M., et al. Polymorphisms in the hMSH2 gene and the risk of primary lung cancer. Cancer Epidem Biomar 15 (2006) 762-768
23. Shih C.M., Kuo Y.Y., Wang Y.C., Jian S.L., Hsu Y.T., Wu H.Y., et al. Association of L-myc polymorphism with lung cancer susceptibility and prognosis in relation to age-selected controls and stratified cases. Lung Cancer 36 (2002) 125-132
24. Shen M.R., Jones I.M., and Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 58 (1998) 604-608
25. Xia L., Shen W., Ritacca F., Mitri A., Madlensky L., Berk T., et al. A truncated hMSH2 transcript occurs as a common variant in the population: implications for genetic diagnosis. Cancer Res 56 (1996) 2289-2292
26. Bubb V.J., Curtis L.J., Cunningham C., Dunlop M.G., Carothers A.D., Morris R.G., et al. Microsatellite instability and the role of hMSH2 in sporadic colorectal cancer. Oncogene 12 (1996) 2641-2649
27. Aebi S., Kurdi-Haidar B., Gordon R., Cenni B., Zheng H., Fink D., et al. Loss of DNA mismatch repair in acquired resistance to cisplatin. Cancer Res 56 (1996) 3087-3090
28. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., et al. The role of MLH1, hMSH3 and MSH2 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Res 58 (1998) 3579-3585
29. Scartozzi M., Franciosi V., Campanini N., Benedetti G., Barbieri F., Rossi G., et al. Mismatch repair system (MMR) status correlates with response and survival in non-small cell lung cancer (NSCLC) patients. Lung Cancer 53 (2006) 103-109
30. Scartozzi M., De Nictolis M., Galizia E., Carassai P., Bianchi F., Berardi R., et al. Loss of hMLH1 expression correlates with improved survival in stage III-IV ovarian cancer patients. Eur J Cancer 39 (2003) 1144-1149
31. Ribic C.M., Sargent D.J., Moore M.J., Thibodeau S.N., French A.J., Goldberg R.M., et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 349 (2003) 247-257
32. Popat S., Hubner R., and Houlston R.S. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23 (2005) 609-618
33. An C., Choi I.S., Yao J.C., Worah S., Xie K., Mansfield P.F., et al. Prognostic significance of CpG island methylator phenotype and microsatellite instability in gastric carcinoma. Clin Cancer Res 11 (2005) 656-663
34. Hishida A., Matsuo K., Hamajima N., Ito H., Ogura M., Kagami Y., et al. Polymorphism in the hMSH2 gene (gIVS 12-6T → C) and risk of non-Hodgkin lymphoma in a Japanese population. Cancer Genet Cytogen 147 (2003) 71-74
35. Fojo T., and Cancer. DNA repair mechanisms, and resistance to chemotherapy. J Natl Cancer Inst 93 (2001) 1434-1436
36. Kim J.C., Roh S.A., Koo K.H., Ka I.H., Kim H.C., Yu C.S., et al. Genotyping possible polymorphic variants of human mismatch repair genes in healthy Korean individuals and sporadic colorectal cancer patients. Fam Cancer 3 (2004) 129-137